Your Partner in Helping to Protect Every Patient from HNSCC
You see them every day—those white or red spots that don't look quite right but don't scream cancer either. The ones that leave you weighing whether to biopsy, monitor, or leave alone.
Now there's a better option for evaluation.​
​
SENTRY Solutions
Non-invasive process for questionable head and neck lesions.
Sentry's non-invasive brush biopsy with AI-assisted analysis lets you sample the full epithelial thickness right in your office, under topical anesthesia. Scalpel-level accuracy without cutting into the submucosa. You get diagnostic clarity while lesions are still treatable and local therapy succeeds in 95% of cases.
​
The numbers tell the story: we've tested 300,000 routine-appearing lesions and found 30,000 cases of high-grade dysplasia and 5,000 cases of carcinoma in situ that would have been missed under "watch and wait." That's 35,000 patients who got intervention before progression to invasive squamous cell carcinoma.
​
For you, it's confidence in your clinical decisions. For your patients, it's either the reassurance they need—or the early intervention that changes everything.
The new Sentry TBx uses this same brush biopsy technique to test an area that is otherwise difficult to see and to sample - the base of tongue.
Neural network tested on tens of thousands of HNSCC cases. “Spell-check for cells” highlights areas for pathologist to review.
​
Expert ENT pathologists combine AI-assisted analysis with quantitative IHC (including P16, p53, Ki-67) to provide a definitive, actionable laboratory report.
About Sentry Laboratories
We are a state-of-the-art laboratory that specializes in the diagnosis of head and neck cancers and dysplasia.
We provide expedient and accurate diagnoses through Augmented Intelligence, integrating proprietary neural networks trained on tens of thousands of Head and Neck cases with experts in ENT pathology. This:
· Increases diagnostic accuracy
· Optimizes sensitivity and specificity through computer-assisted morphology and computer-assisted immunohistochemical testing
· Minimizes pathologists' intra-observer and inter-observer variability
Our Analysis Process
ENT Specialty Laboratory
Your biopsy will be analyzed by the only laboratory that specializes in the diagnosis of Head and Neck cancers and their precursor lesions, dysplasia. All specimens are analyzed by experienced board-certified H&N specialist pathologists.
Neural Network Assisted Morphology for Accurate Disease Identification
Our artificial intelligence-based proprietary software uses neural networks specifically trained on tens of thousands of Head and Neck cases to identify dysplasia and SCC.
Computer-Assisted Molecular Adjunctive Testing
Sensitivity and specificity of computer-assisted morphology is further optimized through computer-assisted immunohistochemical testing of each specimen for HPV (p16) combined with abnormal tumor suppression and cell proliferation markers (p53 and Ki67).
Sentry Clarity Equals Diagnostic Precision
Our proprietary computer-assisted morphologic testing, immunohistochemical staining, and ENT specialty pathologists- all combined- provide you with the highest quality result.
When a precursor lesion is identified, dysplasia can be effectively treated,
potentially preventing HNSCC from ever developing.
A Simple Process. Powerful Results.
EASY TO IMPLEMENT
Biopsy specimen is obtained in the office and submitted to Sentry Labs for analysis via a supplied pre-paid return mailer.
ACTIONABLE DIAGNOSIS
Final pathology report is prepared by expert pathologists with computer-assisted analysis
of specimens based upon morphological evidence and molecular markers.
​
HIGHLY ACCURATE RESULTS
High sensitivity and specificity provide an accurate diagnosis, thereby improving patient outcomes.
Providing Pathologic Results of Common Questionable Head and Neck Lesions
Common-appearing H&N lesions confirmed to be dysplastic or cancerous
Head and Neck Cancer Facts:​​
-
Cancer of the head and neck account for approximately 66,000 cases and 15,000 U.S. deaths annually, with an incidence that is anticipated to increase by 30% by 2030.
-
Risk factors for head and neck cancer include: tobacco and alcohol consumption, gastroesophageal reflux disease, exposure to environmental pollutants and infection with viral agents (HPV and EBV).
-
Despite the fact that HNSCC follows an ordered series of steps beginning with epithelial cell hyperplasia, followed by dysplasia (low grade, high grade), carcinoma in situ and, ultimately, invasive carcinoma, the majority of patients are diagnosed with late-stage disease (Stage III and IV).
-
When detected early, local therapy is effective in up to 95% of patients with early-stage HNSCC. When a precursor lesion is identified, dysplasia can be effectively treated, potentially preventing Head and Neck cancer from ever developing.